DCGO
DocGo Inc.
DCGO's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over DCGO overall, supported by stronger fundamentals and lower modeled downside.
DCGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
DCGO's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
DCGO PE Valuation
DCGO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
DCGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DCGO's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
DCGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.84 | -$1.33 |
| Q2 2026 | -$1.95 | -$1.77 |
| Q1 2026 | -$1.90 | -$1.89 |
| Q4 2025 | -$1.84 | -1122% |
| Q3 2025 | -$0.51 | -289% |
| Q2 2025 | -$0.18 | -167% |
| Q1 2025 | -$0.01 | -105% |
| Q4 2024 | $0.18 | +200% |
DCGO lost $1.84 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over DCGO on earnings quality, reporting a profit while its opponent remains loss making.
DCGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +3.7% |
| Q2 2026 | $73.4M | -8.7% |
| Q1 2026 | $75.6M | -21% |
| Q4 2025 | $74.9M | -38% |
| Q3 2025 | $70.8M | -49% |
| Q2 2025 | $80.4M | -51% |
| Q1 2025 | $96M | -50% |
| Q4 2024 | $120.8M | -39% |
DCGO's revenue has slid since its 2023 peak: $73M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +36 points |
| Q2 2026 | -24% | -2.7 points |
| Q1 2026 | -25% | -10 points |
| Q4 2025 | -140% | -133 points |
| Q3 2025 | -59% | -67 points |
| Q2 2025 | -22% | -28 points |
| Q1 2025 | -15% | -23 points |
| Q4 2024 | -6.2% | -12 points |
DCGO's operating margin was −24% last quarter, up 36 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over DCGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over DCGO on profitability, with a higher operating margin.
DCGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -578% |
| Q2 2026 | -$9.6M | -129% |
| Q1 2026 | -$5.1M | -162% |
| Q4 2025 | -$12M | -200% |
| Q3 2025 | $782.6K | -97% |
| Q2 2025 | $32.9M | +2.1% |
| Q1 2025 | $8.2M | +$19.8M |
| Q4 2024 | $12M | +$21.1M |
DCGO's free cash flow was −$30M over the past year, against $54M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over DCGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -1.6x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -8.4x | Net Cash |
DCGO has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
DCGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 4.2 | Oversold |
DCGO's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
DCGO PE vs Healthcare Sector
| Metric | DCGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DCGO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
DCGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 21% below |
| 20 week MA | $0.43 | 47% below |
| 50 week MA | $0.60 | 62% below |
| 100 week MA | $1.44 | 84% below |
| 200 week MA | $3.57 | 94% below |
DCGO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over DCGO on trend strength, trading above more of its moving averages.
DCGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $10.4 | +0.8% |
| 2021 | $10.4 | $8.71 | -16% |
| 2022 | $8.71 | $6.91 | -21% |
| 2023 | $6.91 | $5.59 | -19% |
| 2024 | $5.59 | $4.38 | -22% |
| 2025 | $4.38 | $0.93 | -79% |
| 2026 YTD | $0.93 | $0.23 | -75% |
DCGO has finished five years in a row lower, and it's down 75% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over DCGO on returns for 2026, with the stronger performance.